- Conditions
- Multiple Myeloma
- Interventions
- Bortezomib, Dexamethasone, Lenalidomide, Acetaminophen, Diphenhydramine, Montelukast, Carfilzomib, Daratumumab, Autologous Stem Cell Transplant (ASCT)
- Drug · Biological
- Lead sponsor
- University of Miami
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 310 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 7
- States / cities
- Miami, Florida • Tampa, Florida • Buffalo, New York + 4 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 258
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Alcohol Use Disorder (AUD), Alcohol-Related Disorders, Alcohol Use
- Interventions
- 0.3mg/kg/min Dimethyltryptamine + Normal Saline infusion, 0.2 mg/kg/min + Dimethyltryptamine 0.01mg/kg/min infusion, 25 mg Diphenhydramine (5 min) + Normal Saline
- Drug
- Lead sponsor
- Yale University
- Other
- Eligibility
- 21 Years to 65 Years
- Enrollment
- 63 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Burn Scar, Itch Scarring, Wound
- Interventions
- Famotidine and 4% topical cromolyn sodium, Placebo
- Combination Product · Other
- Lead sponsor
- The University of Texas Medical Branch, Galveston
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Galveston, Texas
- Conditions
- Multiple Sclerosis
- Interventions
- Cetirizine, Diphenhydramine
- Drug
- Lead sponsor
- University of Miami
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Boca Raton, Florida
- Conditions
- Renal Cell Carcinoma
- Interventions
- BMS-247550, Ranitidine, Diphenhydramine
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 102 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2012
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma, Metastatic Head-and-neck Squamous-cell Carcinoma
- Interventions
- Cetuximab, Questionnaire administration, Quality of life assessment
- Drug · Other
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 1
- States / cities
- Winston-Salem, North Carolina
- Conditions
- Cutaneous Mastocytoses
- Interventions
- Topical preparation of sodium cromolyn 5%, diphenhydramine 1% and trolamine salicylate 10% in emollient cream base.
- Combination Product
- Lead sponsor
- Joseph Butterfield
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Acute Myeloid Leukemia
- Interventions
- RO7283420, Tocilizumab, Dasatinib, Dexamethasone, Paracetamol/acetaminophen, Diphenhydramine
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 59 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 2
- States / cities
- Sacramento, California • Houston, Texas
- Conditions
- Pain, Postoperative
- Interventions
- Naproxen Sodium 440 mg / DPH 25 mg (BAY98-7111), Naproxen Sodium 440 mg (BAYH6689), DPH 50 mg
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 267 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2012
- U.S. locations
- 2
- States / cities
- Austin, Texas • Salt Lake City, Utah
- Conditions
- Kidney Transplant
- Interventions
- Infliximab, Methylprednisolone, Mycophenolate Mofetil, Tacrolimus, Thymoglobulin®, Acetaminophen, Loratadine, Placebo for Infliximab, Prednisone, Diphenhydramine
- Biological · Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 290 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2021
- U.S. locations
- 13
- States / cities
- Birmingham, Alabama • Los Angeles, California • San Francisco, California + 8 more
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
- Interventions
- carboplatin
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 21 Years and older · Female only
- Enrollment
- 146 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2018
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Central Nervous System Effects of Diphenhydramine, Pharmacokinetics of Diphenhydramine
- Interventions
- DiphenhydrAMINE Injectable Solution
- Drug
- Lead sponsor
- Dent Neuroscience Research Center
- Other
- Eligibility
- 35 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022
- U.S. locations
- 1
- States / cities
- Amherst, New York
- Conditions
- Kidney Transplantation, Kidney Disease
- Interventions
- Alemtuzumab, Sirolimus, Tacrolimus, Kidney transplant, Methylprednisolone (or equivalent), Acetaminophen, Diphenhydramine, Trimethoprim (TMP)/Sulfa (Bactrim, Septra), Valgancyclovir, Acyclovir, Pentamidine, Clotrimazole, Nystatin
- Drug · Procedure
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2010
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Lung Cancer
- Interventions
- DOTAP:Chol-TUSC2, Erlotinib, Dexamethasone, Diphenhydramine
- Drug
- Lead sponsor
- Genprex, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2020
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Autonomic Failure, Orthostatic Hypotension
- Interventions
- Atomoxetine, Acarbose, Pyridostigmine Bromide, Yohimbine, Midodrine HCl, placebo, Modafinil, Octreotide, water intake, Diphenhydramine Hydrochloride, Ranitidine HCL, Tranylcypromine, Ergotamine/ Caffeine, Celecoxib, Pseudoephedrine, Methylphenidate, Indomethacin, Ibuprofen, Oxymetazoline 0.05% nasal solution, Bovril, Acetazolamide, Rivastigmine tartrate, Carbidopa/levodopa, Inflatable abdominal binder, inflatable abdominal binder (sham)
- Drug · Other · Dietary Supplement + 1 more
- Lead sponsor
- Vanderbilt University
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 389 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2017
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Community-acquired Pneumonia, Influenza, COVID-19
- Interventions
- Ceftriaxone, Moxifloxacin or Levofloxacin, Piperacillin-tazobactam, Ceftaroline, Amoxicillin-clavulanate, Standard course macrolide, Extended course macrolide, No systemic corticosteroid, Fixed-duration Hydrocortisone, Shock-dependent hydrocortisone, Fixed-duration higher dose Hydrocortisone, No antiviral agent for influenza, Five-days oseltamivir, Ten-days oseltamivir, No antiviral agent for COVID-19, Lopinavir / Ritonavir, Hydroxychloroquine, Hydroxychloroquine + lopinavir/ritonavir, Ivermectin, No immune modulation for COVID-19, Interferon beta-1a, Anakinra, Tocilizumab, Sarilumab, Local standard venous thromboprophylaxis, Therapeutic dose anticoagulation, Conventional low dose thromboprophylaxis, Intermediate dose thromboprophylaxis, Continuation of therapeutic dose anticoagulation, No immunoglobulin, Convalescent plasma, Delayed administration of convalescent plasma, No vitamin C, Vitamin C, No antiplatelet, Aspirin, P2Y12 inhibitor, No simvastatin, Simvastatin, Eritoran, Apremilast, Clinician-preferred mechanical ventilation strategy, Protocolised mechanical ventilation strategy, No renin-angiotensin system inhibitor, Angiotensin converting enzyme inhibitor, Angiotensin Receptor Blockers, ARB + DMX-200, No cysteamine, Cysteamine, Fixed-duration dexamethasone, Baloxavir Marboxil, Five-days oseltamivir + baloxavir marboxil, Ten-days oseltamivir + baloxavir marboxil, No endothelial modulator, Imatinib, No Immune Modulator for Influenza, Baricitinib, Nirmatrelvir/ritonavir, Remdesivir, Nirmatrelvir/ritonavir + remdesivir
- Drug · Other · Biological + 1 more
- Lead sponsor
- UMC Utrecht
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2028
- U.S. locations
- 11
- States / cities
- Jacksonville, Florida • Augusta, Georgia • Chicago, Illinois + 8 more
- Conditions
- Perioperative Optimization
- Interventions
- Neuraxial Analgesia, Regional Block 1: Paravertebral, Perphenazine, Aprepitant, Dimenhydrinate, Ondansetron 4 MG, Dexamethasone, Regional Block 2: QL1
- Drug
- Lead sponsor
- Jennifer Holder-Murray
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 3,395 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 3
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Acute Lymphoblastic Leukemia, in Relapse, Non-Hodgkin's Lymphoma, Relapsed, Non-Hodgkin's Lymphoma Refractory, Acute Lymphoblastic Leukemia With Failed Remission, B-cell Non Hodgkin Lymphoma, B Cell Leukemia
- Interventions
- CD19 specific Chimeric Antigen Receptor T Cell
- Biological
- Lead sponsor
- Nationwide Children's Hospital
- Other
- Eligibility
- Up to 30 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2035
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Migraine, Migraine in Children
- Interventions
- 1/2 maintenance fluids, Ketorolac, Diphenhydramine, Prochlorperazine, bolus
- Other · Drug
- Lead sponsor
- Dayton Children's Hospital
- Other
- Eligibility
- 5 Years to 21 Years
- Enrollment
- 134 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Dayton, Ohio
- Conditions
- Healthy
- Interventions
- lorazepam, diphenhydramine hydrochloride, haloperidol, questionnaire administration, laboratory biomarker analysis
- Drug · Other
- Lead sponsor
- Virginia Commonwealth University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2011
- U.S. locations
- 1
- States / cities
- Richmond, Virginia
- Conditions
- Acute Lymphoblastic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Non Hodgkin's Lymphoma
- Interventions
- CD19CAR/virus specific T cells, Benadryl and Tylenol
- Genetic · Drug
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- Not listed
- Enrollment
- 68 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2031
- U.S. locations
- 2
- States / cities
- Houston, Texas
- Conditions
- Glioblastoma
- Interventions
- Treatment Period 1, Treatment Period 2, Treatment Period 3, Treatment Period 4a
- Drug
- Lead sponsor
- SignPath Pharma, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 2
- States / cities
- Washington D.C., District of Columbia • Baltimore, Maryland
- Conditions
- Stroke, Dye Allergy
- Interventions
- Emergent IV Dye Preparation
- Combination Product
- Lead sponsor
- Global Neurosciences Institute
- Other
- Eligibility
- Not listed
- Enrollment
- 50 participants
- Timeline
- 2015 – 2023
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Acute Liver Failure, Fulminant Hepatic Failure, Hepatic Encephalopathy, Acute Liver Injury, Immune Dysregulation
- Interventions
- High-dose methylprednisolone, Equine anti-thymocyte globulin, Prednisolone, Placebo for prednisolone, Placebo for infusions, Diphenhydramine, Methylprednisolone
- Drug
- Lead sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- NIH
- Eligibility
- 1 Year to 18 Years
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 17
- States / cities
- Los Angeles, California • Palo Alto, California • San Diego, California + 14 more